This thesis explores the intersection of malignancy and solid organ transplantation. First,
establishing that solid organ transplant recipients (SOTRs) are at risk of cancer mortality and …

Over the last few decades, the life expectancy of solid organ transplant recipients (SOTRs)
has improved significantly. With SOTRs living longer, more recipients are dying from cancer …

Background Solid organ transplant recipients (SOTR) with a pretransplant malignancy
(PTM) are at increased risk for cancer recurrence. However, it is unclear whether differences …

Population-based cancer screening recommendations are also suggested for solid organ
transplant recipients (SOTR); however, recommendation adherence is unknown. In a …

Background Active malignancies are a contraindication to transplantation, as
immunosuppression can lead to worse cancer outcomes; therefore, ensuring transplant …

Solid organ transplant recipients (SOTRs) are at increased risk of developing and dying from
cancer. However, controversies exist around cancer screening in this population owing to …

Little is known about the outcomes among solid organ transplant recipients with a
pretransplant cancer diagnosis. We used linked data from the Scientific Registry of …

The overall incidence of cancer is increased 2–3 fold in solid organ transplant recipients
compared to the general population. The increase in risk is not uniform for all malignancies …

Background Solid-organ transplant recipients with pretransplant malignancies (PTM) have
worse overall survival (OS) compared to recipients without history of malignancy. However, it …

Transplant candidates with a history of cancer pose a unique dilemma for clinicians and
patients themselves. On the one hand, it is well known that there is a risk of cancer …